CN102106925B - Medlar polysaccharide and bifidobacterium synbiotic colonic targeting microecological regulator - Google Patents
Medlar polysaccharide and bifidobacterium synbiotic colonic targeting microecological regulator Download PDFInfo
- Publication number
- CN102106925B CN102106925B CN200910217474A CN200910217474A CN102106925B CN 102106925 B CN102106925 B CN 102106925B CN 200910217474 A CN200910217474 A CN 200910217474A CN 200910217474 A CN200910217474 A CN 200910217474A CN 102106925 B CN102106925 B CN 102106925B
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium
- regulator
- microecological
- colonic targeting
- medlar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a medlar polysaccharide and bifidobacterium snybiotic colonic targeting microecological regulator. The medlar polysaccharide and bifidobacterium snybiotic colonic targeting microecological regulator is a Chinese medicinal colonic targeting microecological regulator prepared by putting the mixture of medlar polysaccharide extract, bifidobacterium and carbomer into polyacrylic resin capsules. The medlar polysaccharides are snybiotics, the bifidobacterium is probiotics, the snybiotics can enforce fix planting, growth and colonic targeting formulation of the probiotics, avoid the damage to the probiotics in the stomach and the small intestines and enhance the in vivo growth of the bifidobacterium which is predominant bacteria of human body to achieve the aim of regulate dysbacteriosis of the intestinal tract and regain the microecological balance of human body; the regulator can used for treating intestinal catarrh, diarrhea and constipation due to the dysbacteriosis caused by antibiotics, hormones, immunosuppressants, cytotoxicity medicaments and the like and side effects of the medicaments and simultaneously improve the health state of human body and protect human health.
Description
Technical field: the present invention relates to the segmented intestine targeted microecologic regulator of a kind of LBP bacillus bifidus symphysis unit, belong to Chinese medicine preparation.
Background technology: dysbacteriosis, serious threat human life with healthy, at present; The microecologic regulator of treatment dysbacteriosis both at home and abroad mainly is probiotics preparation (stomach dissolution type), when the colitis that causes with this type of preparation for treating dysbacteriosis, constipation, diarrhoea, promptly discharges medicine because preparation arrives stomach; Make viable bacteria influenced by gastric acid, various enzymes etc. and be damaged; The viable bacteria that can not guarantee sufficient amount gets into colon, and the human body dysbacteriosis mainly refers to colonic flora disequilibrium, therefore; Viable bacteria class microecologic regulator is answered the targeting colon; Could guarantee that viable bacteria gets into field planting, growth site smoothly, recover the intestinal microbial population balance, reach the purpose of the diseases such as bowel dysfunction that the treatment alteration of intestinal flora causes.
Summary of the invention: the shortcoming that the objective of the invention is to overcome common stomach dissolution type microecologic regulator; Provide a kind of LBP bacillus bifidus symphysis unit segmented intestine targeted microecologic regulator; It is obvious to the bowel dysfunction effect that the treatment alteration of intestinal flora causes, it can make medicine in colonic targeting, field planting, growth, dissolving release.The objective of the invention is to realize like this, it is prebiotics with the LBP, and bacillus bifidus is a probiotic bacteria, and the colon adhesion material is a carbomer, and colon colloidal sol capsule material is the polypropylene acid resin.Calculate by a capsules: Lycium barbarum polysaccharide extract or other Chinese medicinal plant polysaccharide or oligosaccharide 0.1-0.2g, bacillus bifidus 0.1g-0.2g, colon adhesion material carbomer 0.05g, colon colloidal sol capsule material is the polypropylene acid resin.Its preparation method is that in the colon colloidal sol capsule of packing into, packing gets final product with Lycium barbarum polysaccharide extract or other Chinese medicinal plant polysaccharide or oligosaccharide, bacillus bifidus, carbomer mixing in proportion.LBP has immunoregulation effect in this invention, can obviously improve cytophagous phagocytic function, improves the lymphocytic multiplication capacity of T; Increase serum IgG content; Strengthen complement activity, resisting fatigue, defying age, blood fat reducing, foster the bifidobacterium growth effect, ischemic brain injury is had the significant protection effect; Can improve the brain function state, also have antibacterial and effect such as hepatoprotective.Bacillus bifidus can form a biological barrier on the intestinal mucosa surface, stops field planting and the invasion of pathogenic bacterium, is used for the bowel dysfunction that alteration of intestinal flora causes; Like acute and chronic diarrhoea; The treatment of constipation, enteritis etc. improves body immunity, simultaneously prevention and the treatment of infecting is had assosting effect.The present invention is with Lycium barbarum polysaccharide extract or other Chinese medicinal plant polysaccharide or oligosaccharide; With bacillus bifidus and carbomer mixing; The Chinese medicine microecologic regulator of packing into and processing in the polypropylene acid resin capsule; It has the effect of keeping and regulate the human body microecological balance, and it promotes probiotic bacteria field planting, growth with prebiotics, and segmented intestine targeted dosage form is avoided the destruction of probiotic bacteria at stomach and small intestinal; For its treatment alteration of intestinal flora provides novel form, treatment of diseases such as colitis, constipation, diarrhoea and China's natural resources of Chinese medicinal materials development and use had positive meaning.Treat dysbacteriosis with microecologic regulator; Can treat and use the dysbacteriosis that antibiotic, hormone, immunosuppressant, cytotoxic drug etc. are caused, the health status that also can promote human body simultaneously, symphysis unit preparation is as microecologic regulator of new generation; With probiotic bacteria and prebiotics Combined application; Bring into play the function of probiotic bacteria and prebiotics simultaneously, prebiotics promotes probiotics field planting in intestinal, growth, breeding, makes probiotic bacteria and prebiotics synergism; Resist the dysbacteriosis disease jointly, safeguard the microecological balance of body.This regulator is through alteration of intestinal flora patient 105 people's clinical practices, and treatment diarrhoea effective percentage reaches 81%.
The segmented intestine targeted microecologic regulator pharmacodynamic experiment data of LBP and bacillus bifidus symphysis unit:
The blank group: prepare above-mentioned 5 kinds of intestinal broth bouillons, aseptic take mice cecal content homogenizing after, respectively the inoculation, cultivate respectively by condition of culture.
LBP group: add LBP solution in the broth bouillon of five kinds of normal intestinal floras respectively,, cultivate respectively by condition of culture by blank control group operation inoculation.
Cultivate the accelerating all of five kinds of floras of back LBP group, and have significant difference more than the blank group.Wherein remarkable with bacillus bifidus, lactobacillus, explain that LBP has the effect that bacillus bifidus promotes its propagation of fostering.
The specific embodiment:
Embodiment 1:
Calculate by a capsules: get Lycium barbarum polysaccharide extract 0.2g, bacillus bifidus 0.1g, colon adhesion material carbomer 0.05g.
Embodiment 2:
Calculate by a capsules: get Lycium barbarum polysaccharide extract 0.1g, bacillus bifidus 0.2g, carbomer 0.05g.
Embodiment 3:
Lycium barbarum polysaccharide extract is other Chinese medicinal plant polysaccharide or oligosaccharide, like one of them of pachyman, ginseng polysaccharide, ganoderan, lentinan, stachyose etc.
Its preparation method is that in the polypropylene acid resin capsule of packing into, packing gets final product with the Lycium barbarum polysaccharide extract of above-mentioned weight, other Chinese medicinal plant polysaccharide or oligosaccharide and bacillus bifidus, carbomer mixing in proportion.
Also can be with bacillus bifidus and carbomer mixing, in the polypropylene acid resin capsule of packing into, or bacillus bifidus to be packed in the polypropylene acid resin capsule, packing gets final product.
Polypropylene acid resin capsule is that Chao Zhou city strong basis pharmaceutical factory produces, and is mainly used in colon targeting drug administration, and this capsule dissolves release according to pH principle insoluble release medicine of separating under stomach and small intestinal pH value condition under colon pH value condition.
This medicine ingredient is analyzed and incompatibility:
This preparation is the compound preparation of Chinese medicine Lycium barbarum polysaccharide extract and bacillus bifidus, is index with the prebiotics polysaccharide, measures the preparation polyoses content with the phenol sulfuric acid process, detects bifidobacteria viable bacteria quantity simultaneously.
Can weaken its curative effect when antacid, antimicrobial drug and this preparation share, should separately take.
Consumption and usage: 2/day, the heavy 0.35g of every capsules.
Claims (2)
1. the segmented intestine targeted microecologic regulator of LBP bacillus bifidus symphysis unit; It is characterized in that: calculate by a capsules: Lycium barbarum polysaccharide extract 0.1-0.2g, bacillus bifidus 0.1-0.2g, colon adhesion material carbomer 0.05g, colon colloidal sol capsule material is the polypropylene acid resin.
2. the method for preparing of the segmented intestine targeted microecologic regulator of the described LBP bacillus bifidus of claim 1 symphysis unit; It is characterized in that: with Lycium barbarum polysaccharide extract 0.1-0.2g, bacillus bifidus 0.1-0.2g, colon adhesion material carbomer 0.05g mixing; Pack in the polypropylene acid resin capsule, packing gets final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910217474A CN102106925B (en) | 2009-12-28 | 2009-12-28 | Medlar polysaccharide and bifidobacterium synbiotic colonic targeting microecological regulator |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910217474A CN102106925B (en) | 2009-12-28 | 2009-12-28 | Medlar polysaccharide and bifidobacterium synbiotic colonic targeting microecological regulator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102106925A CN102106925A (en) | 2011-06-29 |
| CN102106925B true CN102106925B (en) | 2012-09-19 |
Family
ID=44171281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910217474A Expired - Fee Related CN102106925B (en) | 2009-12-28 | 2009-12-28 | Medlar polysaccharide and bifidobacterium synbiotic colonic targeting microecological regulator |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102106925B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105996050A (en) * | 2016-05-12 | 2016-10-12 | 李�浩 | Lactic acid bacterium preparation for improving gastrointestinal function and preparation method |
| CN106265876A (en) * | 2016-10-14 | 2017-01-04 | 青岛自然珍萃生物科技有限公司 | A kind of probiotic composition and the application in alleviation or treatment constipation thereof |
| CN108066296B (en) * | 2016-11-11 | 2020-11-17 | 南京益恒寿生命科技有限公司 | Colon targeting composition containing biological active components and application thereof |
| CN113812622A (en) * | 2021-09-10 | 2021-12-21 | 盛尚杞美(宁夏)生物科技开发有限公司 | Chinese wolfberry tablet for improving human intestinal flora and preparation method thereof |
| CN114057904B (en) * | 2021-11-03 | 2023-04-28 | 沈阳农业大学 | Sulfhydryl radix Codonopsis polysaccharide and application thereof in preparation of colon targeting probiotic microcapsule |
| CN114698848B (en) * | 2022-04-11 | 2024-04-09 | 深圳海创生物科技有限公司 | Active polysaccharide and probiotic composition and application thereof in preparation of health-care food or medicine with constipation relieving effect |
| CN116603069B (en) * | 2023-04-10 | 2024-03-12 | 南方科技大学 | Microorganism targeting implantation system and method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1727465A (en) * | 2004-07-28 | 2006-02-01 | 卢晓蕊 | Wine tea fermented from tea, medlar and Chinese dates |
-
2009
- 2009-12-28 CN CN200910217474A patent/CN102106925B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1727465A (en) * | 2004-07-28 | 2006-02-01 | 卢晓蕊 | Wine tea fermented from tea, medlar and Chinese dates |
Non-Patent Citations (1)
| Title |
|---|
| 李树鹏, 赵献军.黄芪多糖及益生菌合生元对雏鸡肠道微生态区系的影响.《家畜生态学报》.2005,第26卷(第3期),21－25. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102106925A (en) | 2011-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102106925B (en) | Medlar polysaccharide and bifidobacterium synbiotic colonic targeting microecological regulator | |
| EP1596872B1 (en) | Compositions and methods for restoring bacterial flora | |
| CN102014926A (en) | Methods and kits for the treatment of inflammatory bowel disorder conditions | |
| CN113855712B (en) | Composition capable of promoting defecation and application thereof | |
| CN104306981B (en) | Preparation method of anti Helicobacter pylori active antibacterial peptide gastric mucosa nanoparticle delivery system | |
| CN101953985A (en) | Drug with function of removing heat from lung to relieve cough | |
| US20210268051A1 (en) | Methods of using smectite compositions for treating clostridium difficile associated diseases and symptoms | |
| CN114681493B (en) | Application of bifidobacterium animalis subspecies lactis | |
| CN101406489A (en) | Micro-ecological complex bacterial agent and method of preparing micro-ecological complex bacterial agent | |
| CN107998152A (en) | A kind of probiotics tablets of colon release | |
| US20180021399A1 (en) | Composition and use thereof in manufacture of product for improving intestinal function | |
| CN108641991A (en) | A kind of composite viable bacteria preparation and preparation method and its application | |
| CN101336938B (en) | Use of probiotics in preparing composition for treating and preventing hand-foot-mouth disease | |
| CN103893213A (en) | Nano yam polysaccharide biostime colon-targeted microecological modulator | |
| CN101485687B (en) | Medicament for treating gastrointestinal tract disease using biological viable bacteria | |
| CN116966206A (en) | Use of lactobacillus fermentum for the preparation of a product for the prevention and/or treatment of the colon of a laxative | |
| ITMI950378A1 (en) | ASSOCIATIONS OF LACTIC FERMENTS AND SACCAROMYCE LYSATES, THEIR THERAPEUTIC USE AND COMPOSITIONS THAT CONTAIN THEM | |
| CN104013649A (en) | Bacillus licheniformis symbiotic composition and preparations thereof | |
| CN106666738A (en) | Composition used for improving metabolic disorder status of human body and preparation method thereof | |
| CN101450083B (en) | Use of clostridium butyricum in preparing composition for treating newborn feeding intolerance | |
| US20090110663A1 (en) | Method for treatment of bowel disorders | |
| Wu et al. | The Ecological Regulating Effect of Exopolysaccharides Produced by Bifidobacterium on Intestinal Microecological Imbalance. | |
| CN105707898A (en) | Toxin removing and bowel relaxing probiotic composition and preparation method and application thereof | |
| CN108186740B (en) | Medicine prepared from corydalis saxicola bunting extract for treating intestinal disorder and pharmaceutical application thereof | |
| CN111603489A (en) | Microbial inoculum for improving constipation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120919 Termination date: 20161228 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |